On February 6, 2025, at 5:45 p.m. CET, Transgene, a biotech company based in Strasbourg, France, made an important announcement. The company, known for its innovative virus-based immunotherapies for cancer treatment, confirmed that its shares are now eligible for inclusion in the PEA-PME investment scheme.
The PEA-PME scheme, established under the Attractiveness Act in France, is designed to support the financing of small and medium-sized enterprises (PME) and intermediate-sized enterprises (ETI). By including Transgene shares in this scheme, investors can now benefit from the same tax advantages as the traditional PEA investment scheme, while also supporting the growth and development of the company.
Impact on Individual Investors
For individual investors, the inclusion of Transgene shares in the PEA-PME scheme opens up new opportunities for investment in a promising biotech company. By investing in Transgene, investors not only have the potential for financial returns but also contribute to the advancement of cancer treatment through innovative immunotherapies.
Global Implications
The inclusion of Transgene shares in the PEA-PME scheme also has broader implications for the world of biotechnology and healthcare. As Transgene continues to develop virus-based immunotherapies for cancer, its growth and success can have a significant impact on the global fight against cancer. By investing in Transgene, individuals and institutions can play a role in supporting groundbreaking research and advancing the field of oncology.
Conclusion
In conclusion, the confirmation of Transgene shares’ eligibility for the PEA-PME investment scheme represents a significant milestone for the company and its investors. By aligning financial incentives with the development of innovative cancer therapies, Transgene is paving the way for a brighter future in the fight against cancer.
